Intra-cellular Therapies, Inc.

This trial is testing the safety of a medication called lumateperone in children and teenagers who have schizophrenia, bipolar disorder, or autism spectrum disorder. Participants take the drug once daily for 26 weeks, and researchers monitor for side effects. The goal is to see i…

This study tests whether the drug lumateperone can safely reduce symptoms of depression in children and teenagers (ages 10 to 17) with bipolar I or II disorder who are currently in a major depressive episode. Participants receive either lumateperone or a placebo daily for several…

This study tests whether the drug lumateperone can safely reduce irritability in children aged 5 to 17 with autism spectrum disorder. Participants receive either a high or low dose of lumateperone or a placebo daily. The main goal is to see if the drug improves irritability score…

This study tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis symptoms like hallucinations and delusions in people with Alzheimer's disease. About 370 participants will receive either the drug or a placebo, and doctors will track changes in symptom sev…

This study tests an experimental drug called ITI-1284 to see if it can safely reduce agitation in people with Alzheimer's dementia. About 320 participants will receive either the drug or a placebo, and researchers will measure changes in agitated behaviors using a caregiver quest…

This study tests whether adding lumateperone to standard antidepressant therapy can better relieve depression symptoms in adults aged 18 to 65 with major depressive disorder. Participants receive either lumateperone or a placebo daily for several weeks, and researchers measure ch…

This study tests whether the drug lumateperone can safely reduce irritability in children aged 5 to 17 who have autism spectrum disorder. Participants receive either a high dose, low dose, or placebo daily for several weeks. Researchers measure changes in irritability using a sta…

This study tests an experimental drug called ITI-1284 for people with generalized anxiety disorder (GAD) whose current treatment isn't working well enough. About 705 adults will receive either ITI-1284 or a placebo added to their usual therapy. The goal is to see if the drug safe…

This study tests whether a daily tablet called ITI-1284, taken under the tongue, can help people with generalized anxiety disorder whose current treatments aren't working well enough. About 570 adults will receive either the drug or a placebo, and researchers will measure changes…

This study tests a single dose of ITI-1284 in 42 healthy adults aged 18-55. Researchers will use brain scans to see how much of the drug attaches to certain brain receptors. The goal is to gather safety and drug-level information, not to treat any disease.